[New opportunities in the treatment of patients with multiple sclerosis (Resolution of the Council of Experts on April 23, 2022, Moscow, JSC «BIOCAD»)].
N N SpirinYa V VlasovMaria ZakharovaN V KhachanovaE V PopovaF A KhabirovN A TotolyanStella SivertsevaZoya A GoncharovaL L KorsunskayaT I YakushinaO V MatveevskayaT O SimanivAlexey BoykoPublished in: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova (2022)
One of the target areas for the development of the Russian pharmaceutical industry at present is the development of next-in-class drugs medicines. These are original, patent-protected drugs that act on known biological targets, improved or modified in structure and mechanism of action compared to existing, successfully proven medicine. The article presents the results of an expert council on the management of patients with multiple sclerosis and the place of new original medicines of the JSC BIOCAD company (SamPEG-IFN-β1a and divozilimab) in multiple sclerosis therapy algorithm.